PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor.

Abstract Testicular tumors and their treatment interfere with homeostasis, hormonal status included. The aim of the study was to evaluate hormonal disorders of the pituitary-gonadal axis in men treated for testicular tumors. One hundred twenty-eight men treated for a unilateral testicular tumor at our institution were included. The hormonal status was prospectively evaluated in 62 patients before orchiectomy, 120 patients 1 month after orchiectomy and 110 patients at least 1 year after the treatment. The concentrations of human chorionic gonadotropin (hCG), testosterone (T), estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin were measured. The clinically significant testosterone deficiency was defined either as testosterone <2.31 ng/mL or testosterone within the range of 2.31-3.46 ng/mL but simultaneous with T/LH ratio ≤1. Changes in hormone levels were significant: LH and FSH rose in the course of observation, and the concentration of hCG, testosterone, estradiol decreased. PRL concentration was the lowest at 1 month after orchiectomy. In multivariate analysis, the risk of the clinically significant testosterone deficiency was 0.2107 (95% CI 0.1206-0.3419) prior to orchiectomy, 0.3894 (95% CI 0.2983-0.4889) 1 month after surgery and 0.4972 (95% CI 0.3951-0.5995) 1 year after the treatment. The estradiol concentration was elevated in 40% of patients with recently diagnosed testicular cancer and that was correlated with a higher risk of testosterone deficiency after the treatment completion. Hormonal disorders of the pituitary-gonadal axis in men treated for testicular tumors are frequent. The malignant tissue triggers paraneoplastic disorders that additionally disturb the hormonal equilibrium.
PMID
Related Publications

Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones.

Hormonal regulation of testicular prolactin receptors and testosterone synthesis in golden hamsters.

Gonadal function in patients with testicular germ cell tumors.

Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy.

Semen quality and reproductive hormones before orchiectomy in men with testicular cancer.

Authors

Mayor MeshTerms
Keywords

Hormones

Orchiectomy

Testicular tumor

Testosterone

Journal Title medical oncology (northwood, london, england)
Publication Year Start




PMID- 28389909
OWN - NLM
STAT- MEDLINE
DA  - 20170408
DCOM- 20170419
LR  - 20170419
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 5
DP  - 2017 May
TI  - Dynamics of hormonal disorders following unilateral orchiectomy for a testicular 
      tumor.
PG  - 84
LID - 10.1007/s12032-017-0943-0 [doi]
AB  - Testicular tumors and their treatment interfere with homeostasis, hormonal status
      included. The aim of the study was to evaluate hormonal disorders of the
      pituitary-gonadal axis in men treated for testicular tumors. One hundred
      twenty-eight men treated for a unilateral testicular tumor at our institution
      were included. The hormonal status was prospectively evaluated in 62 patients
      before orchiectomy, 120 patients 1 month after orchiectomy and 110 patients at
      least 1 year after the treatment. The concentrations of human chorionic
      gonadotropin (hCG), testosterone (T), estradiol, luteinizing hormone (LH),
      follicle-stimulating hormone (FSH) and prolactin were measured. The clinically
      significant testosterone deficiency was defined either as testosterone &lt;2.31
      ng/mL or testosterone within the range of 2.31-3.46 ng/mL but simultaneous with
      T/LH ratio &lt;/=1. Changes in hormone levels were significant: LH and FSH rose in
      the course of observation, and the concentration of hCG, testosterone, estradiol 
      decreased. PRL concentration was the lowest at 1 month after orchiectomy. In
      multivariate analysis, the risk of the clinically significant testosterone
      deficiency was 0.2107 (95% CI 0.1206-0.3419) prior to orchiectomy, 0.3894 (95% CI
      0.2983-0.4889) 1 month after surgery and 0.4972 (95% CI 0.3951-0.5995) 1 year
      after the treatment. The estradiol concentration was elevated in 40% of patients 
      with recently diagnosed testicular cancer and that was correlated with a higher
      risk of testosterone deficiency after the treatment completion. Hormonal
      disorders of the pituitary-gonadal axis in men treated for testicular tumors are 
      frequent. The malignant tissue triggers paraneoplastic disorders that
      additionally disturb the hormonal equilibrium.
FAU - Wiechno, Pawel J
AU  - Wiechno PJ
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Kowalska, Maria
AU  - Kowalska M
AD  - Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, 
      Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
      Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Kucharz, Jakub
AU  - Kucharz J
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
      [email protected]
AD  - Department of Experimental and Clinical Surgery, Jagiellonian University Medical 
      College, Michalowskiego 12 st., Cracow, Poland. [email protected]
FAU - Sadowska, Malgorzata
AU  - Sadowska M
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Michalski, Wojciech
AU  - Michalski W
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Poniatowska, Grazyna
AU  - Poniatowska G
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Jonska-Gmyrek, Joanna
AU  - Jonska-Gmyrek J
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Rzymkowska, Joanna
AU  - Rzymkowska J
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Nietupski, Karol
AU  - Nietupski K
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
FAU - Demkow, Tomasz
AU  - Demkow T
AD  - Department of Uro-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and
      Institute of Oncology, Roentgena 5 st., 02-781, Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20170407
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Chorionic Gonadotropin)
RN  - 0 (Gonadal Hormones)
RN  - 0 (Pituitary Hormones)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 9002-62-4 (Prolactin)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - 9002-68-0 (Follicle Stimulating Hormone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Chorionic Gonadotropin/metabolism
MH  - Estradiol/metabolism
MH  - Follicle Stimulating Hormone/metabolism
MH  - Gonadal Hormones/*metabolism
MH  - Humans
MH  - Luteinizing Hormone/metabolism
MH  - Male
MH  - Middle Aged
MH  - Orchiectomy/*adverse effects/methods
MH  - Pituitary Gland/metabolism
MH  - Pituitary Hormones/*metabolism
MH  - Prolactin/metabolism
MH  - Testicular Neoplasms/*surgery
MH  - Testis/metabolism
MH  - Testosterone/deficiency/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - Hormones
OT  - Orchiectomy
OT  - Testicular tumor
OT  - Testosterone
EDAT- 2017/04/09 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/09 06:00
PHST- 2017/03/12 [received]
PHST- 2017/04/04 [accepted]
AID - 10.1007/s12032-017-0943-0 [doi]
AID - 10.1007/s12032-017-0943-0 [pii]
PST - ppublish
SO  - Med Oncol. 2017 May;34(5):84. doi: 10.1007/s12032-017-0943-0. Epub 2017 Apr 7.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>